Effect of Repeated Dosing of Clarithromycin on PK of Linaprazan Glurate/Linaprazan, Effect of Single Dose of Linaprazan Glurate on PK of Clarithromycin, Single/Repeated Dosing of Linaprazan Glurate on PK of Midazolam to Healthy Subjects

This is a phase I, open-label, fixed sequence design, drug-drug-interaction (DDI) study divided in 2 parts. Part I is designed to evaluate whether concomitant treatment with linaprazan glurate and clarithromycin, a strong inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein P (PgP), leads to an effect on the systemic exposure to linaprazan glurate and linaprazan and whether there is an effect on the pharmacokinetics of clarithromycin after a single dose of linaprazan glurate. Part II is designed to evaluate the effect of repeated doses of linaprazan glurate on the pharmacokinetics (PK) of a sensitive substrate of CYP3A (midazolam).

开始日期2022-11-27

申办/合作机构

Cinclus Pharma Holding AB

NCT05627518

/ Completed临床1期

A Randomized, Single Dose, Crossover Study in Healthy Volunteers to Investigate the Relative Bioavailability of Linaprazan for a New Oral Tablet Formulation of Linaprazan Glurate, and to Assess the Effect of Food on the Pharmacokinetics of Linaprazan

This is a single-center, open-label, randomized, single dose, 3-way crossover study in healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet formulation of linaprazan glurate in comparison to a previously studied oral tablet formulation under fasting conditions, and to assess the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan after the administration of the new oral tablet formulation.

开始日期2022-11-15

申办/合作机构

Cinclus Pharma AG初创企业

NCT05469854

/ Recruiting临床1期

A Phase I Study to Investigate the Pharmacokinetics and ECG Effects of Two Single Ascending Doses of Linaprazan Glurate Given as Oral Tablets to Healthy Subjects

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized study designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of 2 single ascending oral doses of linaprazan glurate. The study will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses (300 mg, 600 mg, 200 mg and a final dose level of maximum 400 mg) of linaprazan glurate, using 25 mg base formulation (300 mg and 600 mg doses) and 25 mg and 100 mg HCl formulation (200 mg and final dose level of maximum 400 mg) oral tablets.

开始日期2022-07-13

申办/合作机构

Cinclus Pharma AG初创企业

100 项与 Linaprazan 相关的临床结果

登录后查看更多信息

100 项与 Linaprazan 相关的转化医学

登录后查看更多信息

100 项与 Linaprazan 相关的专利（医药）

登录后查看更多信息

项与 Linaprazan 相关的文献（医药）

2024-05-01·Journal of Pharmaceutical and Biomedical Analysis

Absorption, distribution, metabolism and excretion of linaprazan glurate in rats

Article

作者: Liu, Donghui ; Xiu, Jin ; Diao, Xingxing ; Yang, Chen ; Zhang, Xinyue ; Lu, Ming ; Zheng, Yuandong ; Yuan, Yali ; Hu, Pingsheng ; Yang, Ying

Linaprazan (AZD0865, TX07) is one of potassium-competitive acid blockers. However, linaprazan is rapidly excreted from the body, shortening its acid inhibition property. Linaprazan glurate (X842) is a prodrug of linaprazan with a prolonged inhibitory effect on gastric acid secretion. Linaprazan glurate has entered clinical trials, but few studies have reported its metabolism in non-clinical and clinical settings. In this study, we studied the pharmacokinetics, tissue distribution, mass balance, and metabolism of linaprazan glurate in rats after a single oral dose of 2.4 mg/kg (100 µCi/kg) [¹⁴C]linaprazan glurate. The results demonstrated that linaprazan glurate was mainly excreted via feces in rats with 70.48% of the dose over 168 h. The plasma AUC₀_-_∞ of linaprazan glurate in female rats was 2 times higher than that in male rats. Drug-related substances were mainly concentrated in the stomach, eyes, liver, small intestine, and large intestine after administration. In blood, drug-related substances were mostly distributed into plasma instead of hemocytes. In total, 13 metabolites were detected in rat plasma, urine, feces, and bile. M150 (2,6-dimethylbenzoic acid) was the predominant metabolite in plasma, accounting for 80.65% and 67.65% of AUC_0-24_h in male and female rats, respectively. Based on the structures, linaprazan glurate was mainly hydrolyzed into linaprazan, followed by a series of oxidation, dehydrogenation, and glucuronidation in rats. Besides, CES2 is the main metabolic enzyme involved in the hydrolysis of linaprazan glurate to linaprazan.

2020-03-10·Asian Journal of Chemistry

Design, Synthesis and Pharmacological Evaluation of Novel Imidazopyridine Analogues as Proton Pump Antagonist

作者: Patil, Avinash V. ; Sonawane, Ravindra S. ; Patil, Kiran D.

A series of novel imidazopyridine derivatives as proton pump inhibitors was designed with compounds of CID data base and explored considering AZD0865 as standard. Many compounds were identified and docked in proton pump ATPase pocket (PDB ID: 4ux2). Molecular docking studies revealed that many compounds showed good proton pump ATPase inhibitory activity. The docking poses revealed the interaction of ligands with amino acid. The standard drug AZD0865 had docking score of -7.112302 and displayed interactions with Asn138 and Asp137. A series of novel imidazopyridine derivatives as proton pump inhibitors were docked, synthesized and characterized by IR, NMR, CHN and MS spectral analysis. The target imidazopyridines were prepared from substituted 2-aminonicotinic acid and 2-bromo-1-substituted ethanone. in vitro Studies explained that few compounds exhibited moderate to good proton pump ATPase inhibitory activity in comparison with the reference drugs i.e. AZD0865. Compounds 11 and 12 shown higher activities with the IC50 4.3. Compounds 1, 4, 6, 7, 8, 10 and 13 showed weak anti-ulcer activity with its IC50 5.2, 5.8, 5.5, 5.1, 4.9, 4.6 and 5.9 and positive control AZD0865 shown IC50 2.0.

2020-03-01·Journal of Pharmaceutical Sciences

Prediction Characteristics of Oral Absorption Simulation Software Evaluated Using Structurally Diverse Low-Solubility Drugs

Article

作者: Fujita, Takuya ; Tamura, Naomi ; Sugano, Kiyohiko ; Ono, Asami ; Hayashi, Shun ; Haruna, Yuka ; Nakanishi, Misato ; Kimoto, Takahiro ; Matsumura, Naoya ; Fushimi, Masahiro ; Kojima, Yukiko ; Nishiyama, Kotaro ; Kim, Soonih ; Jiko, Maiko ; Akiyama, Yoshiyuki ; Ishida, Masahiro ; Sarashina, Akiko ; Yoneda, Kazuhiro ; Funaki, Satoko

The purpose of the present study was to characterize current biopharmaceutics modeling and simulation software regarding the prediction of the fraction of a dose absorbed (Fa) in humans. As commercial software products, GastroPlus™ and Simcyp® were used. In addition, the gastrointestinal unified theoretical framework, a simple and publicly accessible model, was used as a benchmark. The Fa prediction characteristics for a total of 96 clinical Fa data of 27 model drugs were systematically evaluated using the default settings of each software product. The molecular weight, dissociation constant, octanol-water partition coefficient, solubility in biorelevant media, dose, and particle size of model drugs were used as input data. Although the same input parameters were used, GastroPlus™, Simcyp®, and the gastrointestinal unified theoretical framework showed different Fa prediction characteristics depending on the rate-limiting steps of oral drug absorption. The results of the present study would be of great help for the overall progression of physiologically based absorption models.

项与 Linaprazan 相关的新闻（医药）

2024-12-04

·cincluspharma.com

Linaprazan glurate receives marketing approval in China

Cinclus Pharma, a clinical-stage pharmaceutical company developing molecules for the treatment of gastric acid-related diseases, today announced that its leading drug candidate, linaprazan glurate, has received its first marketing approval for the treatment of gastroesophageal reflux disease (GERD). The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in the People’s Republic of China in 2025. The approved product was developed together with Cinclus Pharma’s partner Jiangsu Sinorda Biomedicine Co., Ltd, (“Sinorda”) in preclinical studies and independently developed in clinical phases in China by Sinorda. The approval of linaprazan glurate in China follows local clinical trials that demonstrated the drug's safety, efficacy, and ability to address a significant unmet need in GERD. Following the approval, pricing and reimbursement discussions will be initiated laying the foundation for expected product launch in China in 2025. “We are thrilled to announce this highly significant marketing approval for linaprazan glurate in China, a market that represents an immense opportunity for expanding access to this innovative treatment. This achievement clearly reflects the strength of our partner Sinorda, our science, and takes us one important step closer to delivering a therapy meeting an unmet need in a global patient population,” said Christer Ahlberg, CEO of Cinclus Pharma. Cinclus Pharma has a license agreement with Sinorda for the development and commercialization of linaprazan glurate in China and other selected regions of Asia. Sinorda sub-licensed the manufacturing and industrial sales rights for linaprazan glurate in China, Hong Kong, Macau and Taiwan to SPH Sine Pharmaceutical Laboratories Co., Ltd, a company within the Shanghai Pharmaceuticals group, one of China’s leading public pharmaceutical and healthcare companies. For additional information, please contact: Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: christer.ahlberg@cincluspharma.com Charlotte Stjerngren, IR Phone: +46 70 876 87 87 e-mail: charlotte.stjerngren@cincluspharma.com About Cinclus Pharma Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com. This information is information that Cinclus Pharma Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-04 15:40 CET. Attachments Linaprazan glurate receives marketing approval in China

引进/卖出上市批准临床2期临床3期

2024-11-22

·cincluspharma.com

Cinclus Pharma agrees on pediatric study plan with FDA

Cinclus Pharma, a clinical-stage pharmaceutical company developing molecules for the treatment of acid-related diseases, today announces that it has reached an agreement with the US Food and Drug Administration (FDA) on the company’s initial Pediatric Study Plan (iPSP). The regulatory agreement on a pediatric study plan is a prerequisite for market approval of a new medicine for adult patients, such as linaprazan glurate. It also provides an opportunity for an expanded approval for use in children. "The agreement on our pediatric study plan with the FDA is a prerequisite for market approval in the US, so it’s really a milestone. Now that we have agreed with both the EMA and the FDA, we have taken an important step towards making linaprazan glurate available to patients, thereby fulfilling a large unmet need. Furthermore, an approved pediatric indication would significantly increase the target population for linaprazan glurate,” said Christer Ahlberg, CEO of Cinclus Pharma. The company’s agreed iPSP mainly includes a clinical efficacy and safety trial where approximately 100 pediatric patients will be treated with linaprazan glurate on the same treatment schedule as in the company’s phase III trials in adult eGERD patients. The study plan is essentially the same as Cinclus Pharma recently agreed with the European Medicines Agency (EMAs) Pediatric Committee (PDCO). A regulatory agreement of a pediatric study plan must be obtained before a sponsor may submit a Marketing Authorization Application for approval to commercialize a new medicine for adult patients. Cinclus Pharma submitted its proposed iPSP to FDA in December 2023 and has been going through the regulatory review processes since then. The company’s agreed iPSP includes a deferral under which the pediatric efficacy and safety trial is anticipated to be undertaken after a Marketing Authorization Application has been submitted. For additional information, please contact: Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: christer.ahlberg@cincluspharma.com Charlotte Stjerngren, IR Phone: +46 70 876 87 87 e-mail: charlotte.stjerngren@cincluspharma.com About Cinclus Pharma Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com. Attachments Cinclus Pharma agrees on pediatric study plan with FDA

临床2期临床3期

2024-10-29

·cincluspharma.com

Cinclus Pharma agrees on Pediatric Investigation Plan (PIP) with EMA

Cinclus Pharma, a clinical-stage pharmaceutical company developing molecules for the treatment of acid-related diseases, today announces that it has reached an agreement with the European Medicines Agency’s (EMA) Paediatric Commmittee (PDCO) on the company’s Pediatric Investigation Plan (PIP). The regulatory agreement on a pediatric study plan is a pre-requisite for marketing approval of a new medicine for adult patients, such as linaprazan glurate. It also provides an opportunity for an expanded approval for use in children. "It is incredibly satisfying that our pediatric study plan has been agreed. It is a prerequisite for market approval in the EU, so it’s really a milestone. In addition, an approved pediatric indication would of course also significantly increase our target population,” said Christer Ahlberg, CEO of Cinclus Pharma. The company’s agreed PIP mainly includes a clinical efficacy and safety trial where approximately 100 pediatric patients will be treated with linaprazan glurate on the same treatment schedule as in the company’s phase III trials in adult eGERD patients. When a new medicine is developed for adult patients, that medicine must also be tested for potential application to pediatric patients. The sponsor must develop an overall plan to select the specific form or stage of the disease to be treated, to adapt the dosing and administration of the medicine for pediatric physiology, and to evaluate the safety and efficacy of the medicine in pediatric patients. A regulatory agreement of a pediatric study plan must be obtained before a sponsor may submit a Marketing Authorization Application for approval to commercialize a new medicine for adult patients. Cinclus Pharma submitted its proposed PIP to EMA in December 2023 and has been going through the regulatory review processes since then. The company’s agreed PIP includes a deferral under which the pediatric efficacy and safety trial is anticipated to be undertaken after a Marketing Authorization Application has been submitted. For additional information, please contact: Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: christer.ahlberg@cincluspharma.com Charlotte Stjerngren, IR Phone: +46 70 876 87 87 e-mail: charlotte.stjerngren@cincluspharma.com About Cinclus Pharma Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com. Attachments Cinclus Pharma agrees on Pediatric Investigation Plan (PIP) with EMA

临床3期临床2期

100 项与 Linaprazan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管反流	临床1期	加拿大	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	丹麦	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	英国	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	法国	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	瑞典	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	德国	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	美国	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	意大利	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	芬兰	AstraZeneca PLC	2004-05-01
胃食管反流	临床1期	挪威	AstraZeneca PLC	2004-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05633147 (CTgov)	临床1期	药物相互作用	35	Linaprazan glurate+Clarithromycin (Part I)	蓋襯願齋膚淵廠齋選膚(膚蓋襯襯襯憲製糧獵鹽) = 願遞憲鏇遞艱選簾鬱蓋鹽遞齋壓簾蓋構鏇積範 (網醖餘夢簾積糧築積鹹, 廠築夢糧選願鑰襯艱夢 ~ 淵選齋顧選獵餘製積窪) 更多	-	2025-01-03
				Linaprazan glurate hydrochloride (HCl)+Midazolam (Part II)	鏇鬱壓積鬱構鑰顧憲簾(餘餘鹹製範齋製壓觸醖) = 觸鹽鹽範選範衊範淵選顧鹹選觸襯鏇鬱憲餘築 (蓋簾鑰齋壓選齋製構遞, 築鏇夢蓋淵製齋襯願壓 ~ 醖鹽艱淵餘獵顧淵蓋簾) 更多